4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
CRISPR Therapeutics AG (CRSP) operates in the Biotechnology industry and is headquartered in Zug, Switzerland. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, CRSP reported $0M in revenue and ($582M) in net income.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Interactive charts & full statements → Open the CRSP valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $35M | $370M | $0M |
| Gross Profit | ($214M) | ($86M) | $240M | ($110M) |
| Operating Income (EBIT) | ($665M) | ($467M) | ($222M) | ($673M) |
| Net Income | ($582M) | ($366M) | ($154M) | ($650M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $1M | $0M | $0M | $0M | $0M |
| Gross Profit | ($45M) | ($54M) | ($57M) | ($45M) | ($58M) |
| Operating Income (EBIT) | ($130M) | ($155M) | ($132M) | ($229M) | ($148M) |
| Net Income | ($123M) | ($131M) | ($106M) | ($208M) | ($136M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $2.3B | $2.2B | $2.2B | $2.2B | — |
| Total Liabilities | $343M | $310M | $347M | $368M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CRSP viewer.
About TickerBase · Data methodology & sources